Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesBone Biologics Corp

Bone Biologics Corp

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.3334 USD 0.01 ( 3.00%)
Last update at 2026-11-06T21:00:00Z
VOLUME
135469
Market Cap
2.48M

Momentum Score

…

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.32
Low
0.35
High
52 Week Price Range
1.05
Low
6.75
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Bone Biologics Corp is a Nasdaq-listed biotechnology company; public disclosures about its operating activities and product pipeline are limited. Long-term growth may depend on clinical and regulatory progress, successful commercialization or licensing deals, and the ability to scale operations, so investors may find exposure to potential upside tied to milestone-driven value creation.
Material risks include development and regulatory failure, limited operating history and liquidity, reliance on external financing with dilution risk, and competitive and commercialization execution challenges.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.32
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-70.17%
Net Debt
-5.33M
ROCE
-60.16%
Diluted EPS TTM
-2.65

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -3.11M -4.11M -8.95M -1.48M -1.61M
Net income -3.11M -4.11M -8.95M 0.70M -1.61M
Selling general administrative 2.17M 2.09M 2.52M 2.09M 1.02M
Selling and marketing expenses - - 2.52M - -
Gross profit - - 0.00M 0.00M 0.00M
Ebit - -4.11M -8.95M -3.67M -1.10M
Ebitda -3.11M 0.11M 0.48M -4.40M -1.10M
Depreciation and amortization - 4.22M 9.43M -0.73M 0.30M
Operating income -3.23M -4.22M -9.43M -3.67M -1.10M
Other operating expenses 3.23M 4.22M 9.43M 3.67M 1.10M
Interest expense - - 2.18M -2.18M 0.81M
Tax provision - - - - 0.00M
Interest income 0.12M 0.06M 0.00M - -
Net interest income 0.12M 0.06M -0.73M -0.73M -0.81M
Income tax expense - -7.32M -2.18M -2.18M 0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 3.23M 4.22M 9.43M 3.67M 1.10M
Cost of revenue - - 0.00M 0.00M 0.00M
Total other income expense net 0.13M 0.11M 0.48M 2.18M -0.51M
Net income from continuing ops -3.11M -4.11M -6.51M -1.48M -1.61M
Net income applicable to common shares - - - - -1.61M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 5.80M 3.86M 3.74M 8.50M 6.68M
Other current assets 0.45M 1.07M 0.71M - -
Total liab 0.42M 0.38M 0.83M 2.55M 0.10M
Total stockholder equity 5.38M 3.48M 2.91M 5.95M 6.58M
Other current liab 0.00M 0.00M 0.47M 2.55M -
Common stock 0.00M 0.00M 0.00M 0.02M 0.01M
Capital stock 0.00M 0.00M 0.00M 0.02M 0.01M
Retained earnings -88.13M -85.02M -80.91M -71.96M -70.48M
Other assets - - - 0.00M -
Cash 5.33M 3.33M 3.03M 7.54M 6.68M
Total current liabilities 0.42M 0.38M 0.83M 2.55M 0.10M
Net debt -5.33M -3.33M -3.03M -7.54M -6.68M
Other stockholder equity 93.51M 88.50M 83.81M 77.89M 77.04M
Total current assets 5.80M 3.86M 3.74M 8.50M 6.68M
Net tangible assets - - - - 6.58M
Net receivables 0.01M - 0.33M - -
Inventory - - -0.33M - -
Accounts payable 0.42M 0.37M 0.36M 0.00M 0.10M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Change to liabilities - - - - -0.37M
Net borrowings - - - - 1.05M
Total cash from financing activities 4.70M 4.42M 5.04M 4.43M 7.90M
Change to operating activities - - - - 0.04M
Net income -3.11M -4.11M -8.95M -1.48M -1.61M
Change in cash 2.01M 0.30M -4.51M 0.86M 6.68M
Begin period cash flow 3.33M 3.03M 7.54M 6.68M 0.00M
End period cash flow 5.33M 3.33M 3.03M 7.54M 6.68M
Total cash from operating activities -2.69M -4.12M -9.56M -3.57M -1.23M
Issuance of capital stock 4.70M 2.62M 8.88M 4.43M 6.86M
Dividends paid - 3.21M - - -
Change to account receivables -0.01M - - - -
Other cashflows from financing activities 4.70M 5.02M 0.01M 4.43M 1.06M
Change to netincome - - - - 0.70M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.17M -0.15M 0.13M -0.17M -0.32M
Stock based compensation 0.26M 0.19M 0.15M 0.27M 0.21M
Other non cash items -0.00M -0.05M -0.89M -2.18M 0.50M
Free cash flow -2.69M -4.12M -9.56M -3.57M -1.23M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
BBLG
Bone Biologics Corp		 0.01
3.00%		 0.33 - - - 0.46 0.13
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Bone Biologics Corp

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

2 Burlington Woods Drive, Burlington, MA, United States, 01803

781 552 4452

https://www.bonebiologics.com

2

Name Title Year Born
Mr. Jeffrey Frelick CEO & Pres 1966
Ms. Deina H. Walsh Chief Financial Officer 1964
Dr. Shun'ichi Kuroda Co-Founder & Member of Scientific Advisory Board NA
Mr. Jeffrey Frelick CEO & President 1966
Ms. Deina H. Walsh CPA Chief Financial Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…